EGFR and acne: Rash or acne and diarrhoeawere the most frequently observed adverse events for both groups thatdemonstrated for more than 50% of the participants of both groups.Patients who exhibited adverse event of ≥ 3 were less in osimertinibgroup (34%) than in standard EGFR-TKI group (45%).10.4% of the patients developed prolongation in QT interval in theosimertinib group, whereas this was 4% for the standardEGFR-TKI group.